Navigation Links
Multiple-drug resistant gene expression pattern predicts treatment outcome for pediatric leukemia

A new study is providing scientists with a better understanding of why some pediatric acute lymphoblastic leukemia (ALL) patients fail to respond to treatment even when existing clinical predictive criteria point towards a positive treatment outcome. The research, published in the April issue of Cancer Cell, is likely to facilitate development of new strategies to combat drug resistance and treatment failure for children with ALL.

Nearly 80% of children with ALL are cured following chemotherapeutic treatment. However, the remaining 20% often exhibit drug resistance and treatment failure that is poorly understood. In some cases, patients are resistant to multiple drugs that have very little structural similarity, suggesting that the mechanisms for drug cross-resistance are probably not the same as mechanisms underlying resistance to a single drug. Dr. William E. Evans from St. Jude Children's Research Hospital and colleagues used a comprehensive genetic screening technique to search for genes that are differentially expressed in ALL cells that demonstrated cross-resistance to two or more commonly used chemotherapeutic agents.

The researchers identified several genes that were differentially expressed in ALL cells that exhibited de novo cross resistance to four widely used antileukemic agents. They went on to investigate the relationship of these genes to treatment outcome in ALL patients and found that expression of the genes was associated with treatment outcome and could be used to identify a subset of patients with a markedly inferior response to treatment. In addition, the findings revealed a previously unrecognized phenotype characterized by discordant resistance to two widely used and mechanistically distinct antileukemic agents and provided new information about the cellular mechanisms involved in disparate response to these drugs.

Specific genetic signatures related to ALL treatment failure and chemotherapeutic cross-resistance were mor e effective at identifying select populations of patients with inferior treatment outcomes than expression patterns associated with resistance to a single drug. "These findings provide new insights into the biological basis of de novo multiple-drug resistance and illuminate potential new targets for overcoming this cause of treatment failure in childhood ALL," explains Dr. Evans.


'"/>

Source:Cell Press


Related biology news :

1. NYCs First Rapid HIV Drug-resistant AIDS Case Prompts Call to Step Up HIV Prevention
2. Drug-resistant bacteria on poultry products differ by brand
3. Genetic discovery could lead to drought-resistant plants
4. UF researchers kill resistant bugs one bandage at a time
5. DDT-resistant insects have additional genetic advantage that helps resistance spread
6. Drug resistant avian influenza viruses more common in Southeast Asia than North America
7. New molecule may aid in production of biofuels and fungi-resistant plants
8. Reducing antibiotic use lowers rates of drug-resistant bacteria
9. New class of antibiotics effective against drug-resistant bacteria discovered in fungi
10. Experimental TB drug effective against resistant and latent mycobacterium tuberculosis
11. Virginia Tech helping to develop higher quality, disease-resistant wheat varieties
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/30/2020)... ... 30, 2020 , ... Accelera Canada , a full-service firm delivering end-to-end ... pleased to announce that the company has opened the doors of its first office ... , “We are so thrilled to now have all our partners and their ...
(Date:1/29/2020)... , ... January 29, 2020 , ... ... and in vitro toxicology testing solutions, has announced a record earnings year for ... weeks, INDIGO showed more than a twenty percent increase in revenue and a ...
(Date:1/28/2020)... OF PRUSSIA, Pa. and CAMBRIDGE, Mass. (PRWEB) , ... ... ... dedicated to solving complex problems for life sciences companies and government agencies, announced ... largest life sciences hubs in the country. Tunnell’s Cambridge office will be in ...
Breaking Biology News(10 mins):
(Date:2/3/2020)... NEW YORK (PRWEB) , ... February 03, 2020 ... ... Quarterly Business Travel, Financial Services Firm Travel, Law Firm Travel, Technology Industry Travel ... of data findings, listed quarterly. Each Index illustrates the following statistics:, ...
(Date:1/28/2020)... ... January 28, 2020 , ... ... Salivary Assay Kits . The new Salivary Total Human IgG Assay Kit ... total immunoglobulin G in saliva, researchers can extend the accuracy and ease of ...
(Date:1/24/2020)... ... January 24, 2020 , ... The ... in biotechnology, diagnostics, therapeutics, laboratory and clinical services during the first two decades ... the world. And as Slone Partners celebrates its 20th anniversary this ...
(Date:1/22/2020)... ... January 21, 2020 , ... Microbial Discovery Group LLC (MDG) ... Industrial and Institutional (I&I) Account Manager. Darrell will focus on servicing MDG’s partners ... over 30 years of sales experience working across multiple different market sectors such ...
Breaking Biology Technology: